NCBiotech Jobs Board ● Connecting North Carolina's life science employers and workforce.

Inhalon Biopharma is a rapidly growing startup with a patented breakthrough technology for preventing and treating acute respiratory infections such as respiratory syncytial virus (RSV), metapneumovirus (MPV) and SARS-CoV-2. The Company just completed a Seed round and has been awarded funding by the US Army to run a Phase 1/2a study in COVID-19 patients and has multiple NIH/SBIR grants to develop its pipeline of treatments for RSV, MPV, and influenza. Inhalon operates out of Durham, NC and the SF Bay Area. The Company plans to start a Phase 1/2a COVID-19 study in mid-2021 and file an IND for its RSV+MPV program in 1H 2022.

Inhalon Biopharma is an equal opportunity employer, and all qualified applicants will receive consideration for employment without regard to age, race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status, or any other characteristic protected by law.
Visit this employer's web site: